Advances in the management of complications from cirrhosis  

作　　者：Jasleen Singh Mark Ebaid Sammy Saab 

机构地区：[1]Department of Surgery,David Geffen School of Medicine at UCLA,Los Angeles,CA,USA [2]Department of Medicine,David Geffen School of Medicine at UCLA,Los Angeles,CA,USA

出　　处：《Gastroenterology Report》2024年第1期659-670,共12页胃肠病学报道(英文)

摘　　要：Cirrhosis with complications of liver decompensation and hepatocellular carcinoma(HCC)constitute a leading cause of morbidity and mortality worldwide.Portal hypertension is central to the progression of liver disease and decompensation.The most recent Baveno VII guidance included revision of the nomenclature for chronic liver disease,termed compensated advanced chronic liver disease,and leveraged the use of liver stiffness measurement to categorize the degree of portal hypertension.Additionally,non-selective beta blockers,especially carvedilol,can improve portal hypertension and may even have a survival benefit.Procedural techniques with interventional radiology have become more advanced in the management of refractory ascites and variceal bleeding,leading to improved prognosis in patients with decompensated liver disease.While lactulose and rifaximin are the preferred treatments for hepatic encephalopathy,many alternative treatment options may be used in refractory cases and even procedural interventions such as shunt embolization may be of benefit.The approval of terlipressin for the treatment of hepatorenal syndrome(HRS)in the USA has improved the way in which HRS is managed and will be discussed in detail.Malnutrition,frailty,and sarcopenia lead to poorer outcomes in patients with decompensated liver disease and should be addressed in this patient population.Palliative care interventions can lead to improved quality of life and clinical outcomes.Lastly,the investigation of systemic therapies,in particular immunotherapy,has revolutionized the management of HCC.These topics will be discussed in detail in this review.

关 键 词：liver cirrhosis hepatocellular carcinoma liver failure 

分 类 号：R57[医药卫生—消化系统]